

**China Development Forum 2021**  
*China on a New Journey of Modernisation*

**9:15-10:15, 20 March 2021**

**Parallel Session I - Venue IV**

**New Opportunities in the Healthy China Initiative**

**Moderator**

Luo Hua, Editor-in-chief, People's Daily Online

**Speakers**

Yu Xuejun, Vice Minister, China National Health Commission

Xu Jinghe, Deputy Commissioner, National Medical Products Administration

Albert Bourla, Chairman & CEO, Pfizer Inc.

Zhang Jianqiu, CEO, Inner Mongolia Yili Industrial Group Co.

Christophe Weber, President & CEO, Takeda Pharmaceutical Company

Milind Pant, CEO, Amway Corporation

**Key points**

- Improvements in people's health awareness after the pandemic will bring about a transformation of the health industry and the optimization and reform of its systems and regimes.
- The dual circulation development pattern will drive international cooperation, system reforms, and scientific and technological innovation to build a Healthy China.
- 2030 will be a milestone in the development of Healthy China. Regulatory systems and regimes will have been improved, and the R&D and innovation capabilities of China's healthcare and life sciences industry will have reached the world's top tier.

**Synopsis**

Building a Healthy China is a key goal in the *Outline of the 14th Five-Year Plan for National Economic and Social Development and the Long-Range Objectives Through the Year 2035*. This session discussed the Healthy China initiative and new opportunities arising from it.

The panelists shared the same view on the general direction of the initiative, which will support the foundation and building of a Healthy China through innovation, and play a fundamental role in socialist modernization.

Addressing the development of innovation reforms, Albert Bourla, Chairman & CEO of Pfizer Inc., Christophe Weber, President & CEO of Takeda Pharmaceutical Company, and Milind Pant, CEO of Amway Corporation, agreed that international cooperation and exchange will be of great help in building a Healthy China. Zhang Jianqiu, CEO of Inner Mongolia Yili Industrial Group Co., pointed out that innovation reforms require the integration of product models, operating models and digital applications. Overall, panelists from the enterprise side put greater emphasis on development through business cooperation, business transformation and innovation.

Yu Xuejun, Vice Minister of China National Health Commission, and Xu Jinghe, Deputy Commissioner of the National Medical Products Administration, shared their thoughts on system and regime reforms, innovation, industry integration and transformation:

- There is a need to promote development of the regulatory system, enhance its modernization and medical product capacity in China
- Achievements have been made in reform of the drug and medical devices examination and approval system. Marketing approvals for urgently needed drugs and medical devices with substantial clinical value can better meet public health needs, and stronger post-market regulation can ensure the quality and safety of medical products.
- Reform of the disease prevention and control system should be accelerated. The system and its mechanisms should be streamlined, and a national public health network should be built to protect people and safeguard economic development.
- Driving the high-quality development of public hospitals. China should strive to achieve the following changes in public hospitals within five years: making quality and efficiency enhancements the basis of development; adopting an operating model based on refined management; and being more focused on people's skills as a way to guide resource deployment.
- Promoting the high-quality development of the health industry. They suggested supply-side structural reform in healthcare be accelerated, people's needs for health services be accommodated, and that there should be a push towards industry transformation, upgrading and integration.

Addressing new opportunities brought that the Healthy China initiative will bring, the panelists emphasised the role of international cooperation in creating new business possibilities, and increasing the depth and breadth of China's healthcare and life sciences industry.

- Milind Pant, CEO of Amway Corporation, said modernization could be achieved by integrating China's traditional medicines and modern science and technology, backed by cooperation in basic research and medical manufacturing.
- Christophe Weber, President and CEO of Takeda Pharmaceutical Company, said international pharmaceutical companies and local companies could join together to develop innovative drugs for the global market and build related ecosystems to

strengthen the healthcare system in China.

- Albert Bourla, Chairman & CEO of Pfizer Inc., said international cooperation could enable the development of commercial health insurance, which can ease pressure on China's public healthcare system and enable more people to enjoy healthcare services.
- Xu Jinghe, Deputy Commissioner of National Medical Products Administration, said it could participate in exchange and cooperation with drug administration bodies across the world, and accelerate the conversion and implementation of international rules in China to contribute more Chinese wisdom and power to drug administrators and human health development.

The development targets of the 14th Five-Year Plan set the tone for the future development of the healthcare industry in China, and have made improving the healthcare system a key factor in improving people's wellbeing to a new level. Given the ideas and suggestions put forward by the panelists, more powerful measures are expected to enable the implementation of Healthy China and further strengthen the foundations of people's health.

<End>

---

*Acknowledgement:* **Deloitte.**  
德勤